MedTrace Logo

Beta-hCG + Erythropoietin in Acute Stroke

NCT00362414 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2016-08-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety of Beta-hCG + Erythropoietin in patients with acute ischemic stroke.

Conditions

  • Acute Stroke

Interventions

DRUG

Dual Growth Factor

10,000 IU Beta-hCG IV on days 1, 3, and 5 of study participation 30,000 IU Erythropoietin IV on days 7, 8 and 9 of study participation

Sponsors & Collaborators

  • Stem Cell Therapeutics Corp.

    collaborator INDUSTRY

  • Hoag Memorial Hospital Presbyterian

    collaborator OTHER

  • University of California, Irvine

    lead OTHER

Principal Investigators

  • Steven C. Cramer, MD, MMSc · University of California, Irvine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00362414 on ClinicalTrials.gov